XML 23 R4.htm IDEA: XBRL DOCUMENT v3.24.2Close
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:    
Consulting expense $ 1,303,342 $ 1,096,245
General and administrative expense 403,589 405,295
Clinical trials 92,466 383,688
Product manufacturing and vial filling 319,507 0
Research and development 110,975 270,529
Total operating expense 2,229,879 2,155,757
Income (loss) from operations (2,229,879) (2,155,757) Close
Other income (expense):    
Interest income 5,265 274
Interest expense (385,236) (1,566,919)
Financing costs 0 (5,124)
Gain on debt forgiveness 50,000 28,000
Original interest debt discount 0 (156,229)
Gain on change in fair value of derivative liabilities 472,168 1,054,786
Total other income (expense) 142,197 (645,212) Close
Net income (loss) before income tax (2,087,682) (2,800,969) Close
Income tax 0 0 Close
Net income (loss) $ (2,087,682) $ (2,800,969) Close
Net income (loss) per share, basic and diluted $ (0.01) $ (0.02)
Weighted average number of shares outstanding, basic and diluted 155,744,233 118,569,028